Center for Cancer Immunology and Immunotherapy: Functional Immunomics Core for Immune Profiling in Cancer
Official title: Center for Cancer Immunology and Immunotherapy (CCII) - Functional Immunomics Core (FIC)
Funded at University of Louisville · NIH-11399782 · Data updated 2026-11-12
A patient-facing center is building advanced immune profiling capabilities to study how immune cells interact with tumors using mouse models, tissue samples, and new imaging technologies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Louisville NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project start | February 1, 2020 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $481,719 |
| NIH project number | 5P20GM135004-07 |
| Project ID | NIH-11399782 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients whose tumors are studied or whose tissue samples may be used in future translational projects.
✕Less likely to help
Not all participants will directly receive a treatment; this is a research infrastructure project.
What this research studies
This grant supports a core facility that provides specialized immune cell analysis and imaging services to researchers studying cancer immunology. It focuses on technologies like CyTOF and imaging mass cytometry to map immune cell types and their spatial relationships within tumors. The core also expands capabilities to sort cells from human and animal tissues and to adopt new technologies quickly. The work aims to identify potential new therapeutic strategies by understanding how different immune cells contribute to tumor progression.
Why it matters
Potential benefit: If successful, the core could accelerate the discovery of immune-based cancer treatments and help translate insights into new therapies.
How similar studies have gone: Prior studies using CyTOF and imaging mass cytometry have shown detailed immune landscapes can guide therapy development.
Where this research is happening
-
University of Louisville
Louisville, United States Active
Researchers
- Principal investigator: Bodduluri, Haribabu — University of Louisville
- Study coordinator: Bodduluri, Haribabu
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.